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Research articleInterleukin-10 production by tumor infiltrating 
macrophages plays a role in Human Papillomavirus 
16 tumor growth
Aline Bolpetti1, João S Silva2, Luisa L Villa3 and Ana Paula Lepique*3
Abstract
Background: Human Papillomavirus, HPV, is the main etiological factor for cervical cancer. Different studies show that 
in women infected with HPV there is a positive correlation between lesion grade and number of infiltrating 
macrophages, as well as with IL-10 higher expression. Using a HPV16 associated tumor model in mice, TC-1, our 
laboratory has demonstrated that tumor infiltrating macrophages are M2-like, induce T cell regulatory phenotype and 
play an important role in tumor growth. M2 macrophages secrete several cytokines, among them IL-10, which has 
been shown to play a role in T cell suppression by tumor macrophages in other tumor models. In this work, we sought 
to establish if IL-10 is part of the mechanism by which HPV tumor associated macrophages induce T cell regulatory 
phenotype, inhibiting anti-tumor activity and facilitating tumor growth.
Results: TC-1 tumor cells do not express or respond to IL-10, but recruit leukocytes which, within the tumor 
environment, produce this cytokine. Using IL-10 deficient mice or blocking IL-10 signaling with neutralizing antibodies, 
we observed a significant reduction in tumor growth, an increase in tumor infiltration by HPV16 E7 specific CD8 
lymphocytes, including a population positive for Granzyme B and Perforin expression, and a decrease in the 
percentage of HPV specific regulatory T cells in the lymph nodes.
Conclusions: Our data shows that in the HPV16 TC-1 tumor mouse model, IL-10 produced by tumor macrophages 
induce regulatory phenotype on T cells, an immune escape mechanism that facilitates tumor growth. Our results point 
to a possible mechanism behind the epidemiologic data that correlates higher IL-10 expression with risk of cervical 
cancer development in HPV infected women.
Background
High risk human papillomavirus, HR-HPV, is the main
etiologic factor for cervical cancer and for a percentage of
other anogenital and oropharyngeal tumors [1].
Immune responses against HPV antigens eliminate
most of the infections and precursor lesions in women.
Moreover, only a percentage of the infected women show
persistent infection that leads to malignant disease [2,3].
Persistent infection is inevitably linked to immune eva-
sion mechanisms. HPV display several mechanisms for
evading the host's immune system, for example: mainte-
nance of low viral protein levels in the cell, expression of
capsid proteins only in external layers of the epithelium
and therefore out of reach of antigen presenting cells [4],
inhibition of interferon responsive element [5,6], and pro-
duction of regulatory cytokines like TGFβ[7,8]. More-
over, tumor cells also display evasion mechanisms which,
in the case of HPV associated tumor cells, are not well
established. One cytokine which expression has been
associated with HPV related disease is IL-10 [9-11]. IL-10
is a pleiotropic cytokine produced by myeloid cells and
lymphocytes that displays both immunoregulatory and
immunostimulatory effects [12]. IL10 inhibits the pro-
duction of other cytokines such as Interleukin-2 (IL-2),
Interferon γ (IFNγ), Interleukin-12 (IL-12), Tumor
Necrosis Factor α (TNFα) and it is also associated to
Major Histocompatibility Complex-I (MHC-I) downreg-
ulation [13,14] resulting in reduction of Th1 response.
Different studies have reported increased IL-10 serum
levels in patients with melanoma [15] and other solid
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tumors [16], as well as expression of IL-10 by tumor cells
[17-19]. In cervical cancer patients, IL-10 is secreted by
regulatory CD4 lymphocytes stimulated with HPV anti-
gens [20]. Higher expression of IL-10 in cervical tissue
correlates with higher grade lesions [21-23]. Further-
more, polymorphisms in IL-10 gene promoter have been
associated with susceptibility to precursor lesions associ-
ated to HPV infection as well with infection clearance
[24,25].
Tumor associated macrophages and myeloid derived
suppressor cells express IL-10, among other cytokines, as
part of the mechanism of suppression of T cell anti-
tumor responses [26-28]. Interestingly, increased num-
bers of macrophages per lesion area have been associated
with higher grade cervical disease [29-31].
Our laboratory has been investigating the role of tumor
associated myeloid cells in the HPV16 mouse tumor
model, TC-1. We have previously shown that TC-1
tumors are infiltrated mainly by CD45+CD11b+F4/
80+Arginase1+ macrophages, as well as some
CD45+CD11b+Gr1+ cells [32]. In the present study we
tested the hypothesis that IL-10 is part of the mechanism
by which tumor infiltrating macrophages inhibit anti-
tumor T cell activity [32]. We injected TC-1 cells in IL-10
deficient mice or mice treated with anti-IL10 and anti-IL-
10R neutralizing antibodies. In these mice, tumors exhib-
ited delayed growth kinetics and higher infiltration by
CD4 and CD8 lymphocytes, including E7 HPV16 specific
CTL Perforin+ cells. Furthermore, we observed that IL-10
is necessary for the expansion of B cells in the lymph
nodes of tumor bearing mice. Altogether, our results
point to IL-10 as one of the elements involved in tumor
immune evasion via T cell regulatory phenotype induc-
tion.
Methods
Mice and cell lines
C57Bl/6 and C57Bl/6 IL-10tmlCgn (B6.129P2-Il10tm1Cgn/J
#002251) mice [33] were maintained in standard mouse
facility at the Faculdade de Medicina, Universidade de
São Paulo (Ribeirão Preto, SP, Brazil) with irradiated food
and autoclaved water, with cycles of light and dark of 12
hours.
Alternatively, C57Bl/6 mice used for the neutralizing
antibodies assays were maintained at the Ludwig Institute
for Cancer Research mouse facility in spf (specific patho-
gen free) conditions. All mouse protocols were approved
by the Ethics Committee for Animal Experimentation of
Fundação Antônio Prudente, São Paulo, Brazil, protocol
05/05.
TC-1 cell line was kindly donated by Dr. TC Wu (John
Hopkins, Baltimore, MD). This cell line is derived of lung
epithelium transformed with HPV16 E6 and E7 onco-
genes and Ha-ras [34]. These cells were cultivated in
RPMI supplemented with 10% bovine fetal serum and
400 μg/ml Neomicin (Invitrogen, Carlsbad, CA) in incu-
bators with atmosphere of 5% CO2.
Tumor formation
TC-1 cells were suspended in Phosphate Buffered Saline,
PBS++ (1 mM CaCl2, 0.5 mM MgCl2) at a concentration of
105cells/100 μl of suspension. Each mouse was injected
with 105 TC-1 cells subcutaneously in the right dorsal
flank. Tumor formation and size was measured with a
caliper until a maximum diameter of 1.5 cm. Mice were
observed and measured with intervals of 2 or 3 days from
the day when they were injected. Tumor volume was cal-
culated using the formula V = D*d2/2, where V is the
tumor volume, D is the largest tumor measured diameter
and d is the smallest measured tumor diameter.
Neutralizing antibody treatment
Mice received intraperitoneal doses of 10 mg of anti-IL-
10 antibody (mAb417 R&D Systems, Minneapolis, MN)
alternated with intraperitoneal doses of 10 μg of anti-IL-
10R antibody (AF-474-NA, R&D Systems, Minneapolis,
MN) spaced by 4 days. The first dose was given in the
same day as the TC-1 cells injection and it was a double
dose of anti-IL-10 and anti-IL-10R. Alternatively, mice
were treated with 500 μg of protein G purified antiIL10R
clone 1B13a. As controls, mice were treated with equal
amounts of rat IgG, catalog number 6-001-A (R&D Sys-
tems, Minneapolis, MN) or catalog number I4131
(Sigma-Aldrich, St Louis, MO).
Cell preparations
All cell preparations were performed in 1× Hanks' buff-
ered saline solution supplemented with 5% fetal bovine
serum and 0.5 U/ml DNase.
For tumor preparations, these were harvested after
mouse euthanasia, a fraction was frozen in Tissue-Tek
OCT (Sakura Finetek Europe, NL) for immunofluores-
cence studies, the rest of the tumor was minced and
digested in 100 μg/ml Collagenase under agitation at
37°C for 1 to 2 hours. The cell suspension was filtered
through a 70 μm mesh and washed twice before use.
Spleen and lymph node suspensions were made by
mechanical dissociation of the tissue and filtration
through nylon mesh. Splenocytes were submitted to
hypotonic cell lyses to eliminate red cells. Peritoneal mac-
rophages were harvested after mouse euthanasia; by
injecting 5 ml ice cold PBS into the peritoneal cavity and
aspiration of the solution containing the resident cells.
Bolpetti et al. BMC Immunology 2010, 11:27
http://www.biomedcentral.com/1471-2172/11/27
Page 3 of 13
After centrifugation, cells were ressuspended in Hanks'
buffer, counted and used for macrophage sorting.
FACS analysis
Single cell suspensions were incubated with the antibod-
ies indicated in each figure. Tumor and spleen suspen-
sions were blocked with Fc ligand (CD16/CD32, clone
2.4G2) (BD Biosciences, San Diego, CA) before incuba-
tion with the specific antibodies. The antibodies used in
this work were anti-CD4 (cloneGK1.5), anti-CD8 (clone
53-6.7), antiGr1 (clone RB6-8C5), anti-CD11b (clone M1/
70), anti-CD19 (clone 1D3), anti-CD45 (clone 30-F11),
anti-IL-10 (clone JES5-16E3) purchased from BD Biosci-
ences (San Diego, CA), PE-Cy5.5 conjugated F4/80 (clone
BM8) and APC conjugated anti-Perforin were purchased
from eBiosciences (San Diego, CA). MHC-I tetramers
containing the HPV16 E749-57 epitope or an irrelevant
peptide were a kind donation from Dr. Immanuel Lue-
scher and Dr. Philippe Guillaume (Ludwig Institute for
Cancer Research, Lausanne, Switzerland). The lympho-
cyte populations were analyzed after gating on the
CD45+F4/80- compartment. For intracellular staining,
cells were incubated with antibodies against surface
markers first, then fixed and permeabilized with Cytofix/
Cytoperm kit from BD Biosciences (San Diego, CA). Cells
were analyzed in a FACSCalibur (BD Biosciences, San
Diego, CA). The number of acquired events is indicated
in the figure legends. For cell cycle analyzes, TC-1 cells
were harvested by tripsinization, fixed in 4% buffered
formaldehyde and incubated in a buffer containing 0.1%
(v/v) Triton X-100, 0.2 mg/ml RNase (DNase free)
(Sigma, St Louis, MO) and 10 mg/ml propidium iodide
(BD Biosciences, San Diego, CA) for 15 min at 37°C with
gentle agitation. Cells were subsequently washed and
analyzed in a FACSCalibur (BD Biosciences, San Diego,
CA).
Cell sorting
CD45+ cells were sorted from total tumor suspensions by
positive selection after incubation with biotin conjugated
anti-CD45 and streptavidin conjugated magnetic beads
(Miltenyi Biotec, Germany) and loading in columns
exposed to magnetic field (MACS LS+ Separation Col-
umns) (Miltenyi Biotec, Germany). The negative fraction
was used as CD45- population for RNA expression ana-
lyzes. In general, we obtained 95% pure cells with at least
90% viability.
Peritoneal macrophages were sorted from the perito-
neal resident cells by positive selection with purified anti-
F4/80 antibody, followed by anti-rat PE and and isolation
using the EasySep anti-PE magnetic beads (Stem Cell
Technologies, Vancouver, CA).
For protein expression experiments, tumors were
digested as described before, and single cell suspensions
were blocked with Fc blocking reagent and stained with
FITC conjugated anti-CD11b, PE conjugated anti-Gr1,
PECy5.5 conjugated anti-F4/80 and APC conjugated anti-
CD45. Populations CD45+CD11b+F4/80+ or
CD45+CD11+Gr1+ were sorted in a FACSCalibur (BD
Biosciences, San Diego, CA). These sortings resulted in
populations with 90-95% viability, approximately 90%
purity for the F4/80+ population, which is the most abun-
dant in the tumors, and approximately 80% purity for the
Gr1+ population.
Lymphocyte ex-vivo cultures
Total cell suspensions from peripheral lymph nodes were
seeded in 24 well culture dishes, 1 × 106 cells/well in 10%
fetal bovine serum and stimulated with 15 μg/ml each
HPV16 E749-57 peptide and HPV16 E6. After 5 days of
incubation, cells were harvested, stained with anti-CD4
(cloneGK1.5), anti-CD8 (clone 53-6.7), fixed and stained
with anti-Foxp3 (clone FJK-16S) using the FITC anti-rat/
mouse Foxp3 staining set (eBioscience, San Diego, CA).
Cells were analyzed by flow cytometry, when 100.000
events were acquired for posterior analyzes.
RNA analysis
Cytokine expression analyses were performed by RT-PCR
using RNA obtained from tumors collected 20 days post
injection of TC-1 cells. Total RNA was extracted from
infiltrating leukocytes (CD45+) and tumor cells (CD45-)
using the RNeasy mini kit (Qiagen, Germany) according
to the manufacture's recommended protocol. cDNA syn-
thesis was performed using M-MLV reverse transcriptase
(Invitrogen, Calrsbad, CA), oligo-dT and random prim-
ers, according to the manufacturer recommendation. We
used 50 ng of cDNA in each amplification reaction.
Expression of the constitutive gene HPRT was used as
internal control. Amplified fragments were resolved in
1% agarose gels stained with 0.5 μg/ml ethidium bromide
(Sigma-Aldrich, St Louis, MO).
Quantitative Real-time PCR analyses for IL-10 expres-
sion were done in CD45+ and CD45- cells isolated from
TC-1 tumors. The reaction was performed in an ABI
7300 detection system (Applied Biosystems, Foster City,
CA) with SYBR Green Mastermix (Applied Biosystems,
UK) and specific primers for IL-10 (Forward CCCTG-
GGTGAGAAGCTGAAG and Reverse CACTGCCTT-
GCTCTTATTTTCACA) and GAPDH (Forward
GGGCTGGCATTGCTCTCA and Reverse TGCTG-
TAGCCGTATTCATTGT). The relative quantification of
IL-10 in comparison to a reference gene (GAPDH) was
determined as described [35]. The relative expression
ratio was calculated based on Real-time PCR efficiency
and the crossing points for the IL-10 and GAPDH tran-
scripts. The following formula was applied Ratio = EIL-
10(Ctcontrol-Ctsample)/EGAPDH(Ctcontrol-Ctsample), where E is the
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efficiency, Ctcontrol and Ctsample are the cycle numbers
where GADPH and IL-10 amplification is detected above
the threshold, respectively.
In order to analyze a panel of genes involved in the
inflammatory response in our tumor model, Mouse
Inflammatory Cytokines and Receptors RT2 Profiler PCR
Array System (PAMM-011A) were used (SABiosciences
Corporation, Frederick, MD). RT2 Profiler PCR Array
System analysis was performed using cDNA obtained
from total RNA of CD45+ and CD45-sorted cells. Samples
of cDNA were synthesized with M-MLV reverse tran-
scriptase (Invitrogen, Carlsbad, CA), oligo-dT primer
(IDT) and random primers. The reactions were per-
formed on an ABI Prism 7300 sequence detection system
(Applied Biosystems, Foster City, CA) using SYBR Green
Mastermix (Applied Biosystems, UK). The mRNA
expression levels were calculated as the ratio of the Ct
averages of the housekeeping genes (HKG) and the Ct
averages of the target gene (TG), where Ct (Cycle thresh-
old) is the number of amplification cycles required for
detection of fluorescence in a given cDNA sample. The
amplification efficiencies of the targets (TG) and refer-
ences (HKG) displayed no significant differences (data
provided by SABiosciences Corporation, Fredrick, MD).
Immunohistochemistry
Ice-cold acetone fixed 5 μm cryo-sections were blocked
with 5% fetal bovine serum in PBS for 30 min at room
temperature prior to incubation with biotinylated pri-
mary antibodies. The ABC Vectastain kit (Vector Labo-
raboratories, Burlingame, CA) was used for antibody
detection, followed by Mayer's hematoxylin counterstain-
ing and slide mounting in Permount (Fisher Scientific,
Pittsburgh, PA). Images were obtained with an IX70
Olympus fluorescence microscope (Olympus, Corp.
Tokyo, Japan), a DP70 Olympus camera, using its own
software.
Immunofluorescence
Acetone/methanol (2:1 v/v) fixed 5 μm cryo-sections
were blocked with 5% fetal bovine serum in PBS for 30
min at room temperature prior to incubation with pri-
mary antibodies. Anti-CD8 antibody (clone 53-6.7, BD
Biosciences, San Diego, CA), was incubated for 30 min
after blocking. Tetramers (a kind donation from Dr. Lue-
scher laboratory, Ludwig Institute for Cancer Research,
Lausanne, Switzerland) were incubated for 2 hours at
room temperature. Tissue was counterstained with 4'6-
diamidino2-phenylindole (DAPI) (Sigma-Aldrich, Saint
Louis, MO). For Granzyme B staining, sections were
fixed in 4% formaldehyde after anti-CD8 staining and
washing, washed, blocked and permeabilized with 5%
FBS, 0.5% Triton X-100, 1 mg/ml rat IgG. Anti-Granzyme
B (clone 16G6, eBiosciences, San Diego, CA) was incu-
bated for 30 min at room temperature, followed by coun-
terstaining with DAPI. Slides were mounted with Prolong
(Invitrogen, Carlsbad, CA). Images were obtained with a
BX61 Olympus fluorescence microscope (Olympus,
Corp. Tokyo, Japan), a DP70 Olympus camera, using its
own software.
Cell cycle analysis
TC-1 cells were seeded in a density of 5 × 104 cells/well in
24 well plates in 10% calf serum supplemented RPMI.
Cells were treated with 0 to 300 ng/ml of IL-10 for 4 days,
after which cells were harvested by trypsinization. After
washing in PBS, cells were fixed with 3.7% buffered form-
aldehyde for 24 hours at 4°C. Cells were washed twice
with PBS and incubated for 45 min at 37°C in a 0.1% (v/v)
Triton X-100, 200 μg/ml DNase free RNase A (Sigma, St
Louis, MO), 10 μg/ml propidium iodide (BD Biosciences,
San Diego, CA). Cells were washed once before acquisi-
tion in a FACSCalibur (BD Biosciences, San Diego, CA).
Statistical analyses
Tumor growth kinetics experiments were tested by
Mann-Whitney. Data from all other experiments were
tested by t-test. In all cases, p < 0.05 was considered sig-
nificant.
Results
Leukocytes infiltrating TC-1 tumors express IL-10
TC-1 cells express E6 and E7 from HPV16 [34]. These
two proteins are responsible for the maintenance of the
transformed phenotype of HPV associated tumor cells, as
well as for most of the immune evasion mechanisms dis-
played by these tumors [4]. TC-1 cells injected into
C57BL/6 mice form tumors within 10 days after injection
(Fig. 1A). Histological analysis of these tumors showed
leukocyte infiltrate distributed all over the tumor area
(Fig. 1B). This result was confirmed by immunohis-
tochemistry showing CD45+ cells representing the total
leukocyte population, distributed throughout the tumor
(Fig. 1C, left panel). We also observed that most of the
infiltrate is of myeloid origin, CD11b+ cells (Fig. 1C, mid-
dle panel). No T cells, identified by anti-CD3, were found
in TC-1 tumors by this method (Fig. 1C, right panel).
CD11b+ tumor infiltrating cells may correspond to a
number of populations from myeloid derived suppressor
cells (MDSC) to tumor associated macrophages [27], or
even granulocytes. Data from our laboratory indicate that
most of these cells are tumor infiltrating macrophages
with a M2-like phenotype [32].
Tumor inflammatory infiltrate may contribute to tumor
fate and immune responses against tumors [26-28]. Aim-
ing to characterize the tumor environment and how the
tumor infiltrating population influences the anti-tumor
immune responses, we analyzed cytokine expression in
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the CD45+ and CD45- tumor cell populations. Initially, we
investigated mRNA expression of cytokines by RT-PCR.
We observed that TGFβ and M-CSF are expressed by
both CD45- tumor cells as by the CD45+ infiltrate. Other
cytokines were exclusively expressed by the leukocyte
infiltrate: IL-10, TNFα and IFNγ (Fig. 2A). To quantify
IL-10 expression, RNA samples from total tumor tissue,
CD45+ and CD45- sorted cells were analyzed by real time
PCR. Compared to the IL-10 expression in the total
tumor population, CD45+ cells produced 700 times more
IL-10 mRNA than CD45- cells (Fig. 2B). Accordingly,
using the SuperArray RT-PCR platform, we observed sig-
nificantly higher expression of IL-10 and its receptors
chains correspondent mRNAs in CD45+ than in CD45-
cell samples (Fig. 2C). Other genes that were more
expressed in CD45+ cells than in CD45- cells were: Integ-
rin αM (ITGAM), TNFα and TNF receptor b
(TNFRsf1b). TGFβ and TNFRsf1a displayed high expres-
sion in both tumor cell compartments, while IL-4 and
IFNγ had low expression levels (Fig. 2C).
Besides RNA expression, we also demonstrated IL-10
protein expression in tumor infiltrating macrophages.
Fig. 2C shows IL-10 intracellular staining of TC-1 tumor
cells (histogram gated on R7), CD11b+ infiltrating popu-
lation (histogram gated on R1 and R2 and R5) and on the
macrophage population CD11+F4/80+ (histogram gated
on R1 and R2 and R4). The only population that
expressed intracellular IL-10 was the macrophage popu-
lation. We tested the CD11+Gr1+ population, but this
population was also negative for IL-10 expression (data
not shown).
Our cytokine expression data indicate that TC-1
tumors infiltrating myeloid cells display a mixed cytokine
profile including pro-inflammatory cytokines like TNFα,
as well as potentially suppressive cytokines like IL-10 and
TGFβ.
Figure 1 Characterization of TC-1 derived tumors. A. Tumor growth kinetics after injection of 105 TC-1 cells in the dorsal flank of C57BL/6 mice. 
Results are the average of tumor measures from 9 mice. B. Histology of TC-1 tumors. Tumor cryo-sections stained with hematoxylin/eosin exemplifying 
areas of leukocyte infiltrate, circulated by doted lines (100 × magnification). Arrows indicate some of the blood vessels. C. Immunohistochemistry char-
acterization of TC-1 tumors. Tumor cryo-sections were incubated with antibodies against the indicated molecules. Antigen-antibody reaction was de-
tected through peroxidase/DAB staining. Positive controls for each antibody are in the insets in each panel (200 × magnification).
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Figure 2 Analysis of cytokine expression in TC-1 tumors. RNA samples from CD45+ and CD45-sorted cells were used for cytokine expression anal-
ysis. A. Qualitative cytokine mRNA expression analysis in total RNA samples from tumors 20 days post-injection. HPRT (Hypoxanthine Guanine Phos-
phoribosyltransferase) was used as control. C+ -positive control RNAs from cells stimulated with different cytokines. No -reactions without addition 
of cDNA. B. Quantitative Real-time PCR analysis of IL-10 expression in CD45+ and CD45- tumor fractions compared to RNA from total tumor population. 
Relative expression ratio is calculated based on ΔΔCt method. C. Results from SuperArray RT-PCR. Data is presented as the ratio of the housekeeping 
genes Ct (HKG) and the target gene Ct (TG). Ratios above 0.6 were defined as positive expression (dashed line). Light gray bars - CD45+ cells cDNA, 
and dark gray bars - CD45- cells cDNA. Asterisks indicate p < 0.05 tested by t-test comparing CD45+ and CD45- expression. D. IL-10 intracellular staining. 
Cell suspensions were stained with anti-CD11b and anti-F4/80 before fixation and with anti-IL-10 after fixation and permeabilization. FACS analysis 
was performed in a FACSCalibur, where the CD11b+ population (top histogram, R1) was used to define the R2 region in the FSCxSSC plot. The CD11b 
× F4/80 plot was gated on R2 and the histograms representing IL-10 expression were gated on R1 and R2 and R4 or R5, CD11b+F4/80+ macrophages 
or the CD11b+ population, respectively; IL-10 expression in the tumor cells corresponds to cells gated on R7. Result representative of 3 independent 
experiments.
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IL-10 facilitates tumor growth
Macrophages associated to TC-1 tumors play a role in
tumor growth. When we depleted this population from
animals, using clodronate liposomes, we observed
decreased tumor growth and an increase in expansion of
CD8 specific T cells in the spleen, as well as infiltrating
the tumors [32]. As we demonstrated, these macrophages
express IL-10 (previous section and [32]). Due to the
described roles of IL-10 in the literature, we raised the
hypothesis that IL-10 may be involved in the mechanism
by which this macrophage population facilitates tumor
growth. We first tested whether IL-10 treatment had any
effect on TC-1 proliferation in vitro. As shown in Fig. 3,
increasing concentrations of recombinant IL-10 had no
effect on TC-1 cell cycle, indicating that proliferation of
TC-1 is not regulated by IL-10. We continued our investi-
gation by injecting TC-1 cells in IL-10 deficient mice or
mice treated with neutralizing antibodies against IL-10
and/or IL-10R (same effect was observed treating mice
with alternate doses of 10 μg of anti-IL-10 and anti-IL-
10R from R&D Systems or doses of 500 μg of the anti-IL-
10R 1B13a monoclonal antibody purified in our labora-
tory). TC-1 tumor growth in IL-10 knockout was signifi-
cantly slower than in wild type mice (Fig. 4A ‡). In mice
treated with anti-IL-10 neutralizing antibodies, we also
observed a significant reduction in tumor growth in com-
parison with C57BL/6 mice (Fig. 4A *). Significant reduc-
tion in tumor growth was also observed when anti-IL-10/
IL-10R antibody treated mice were compared with tumor
growth in mice treated with irrelevant IgG in the same
amount, and doses, as the specific antibodies. This con-
trol group showed a partial effect in reducing tumor
growth, which could be due to activation and recruitment
of neutrophils (to be published elsewhere). Nevertheless,
the mice treated with anti-IL10/IL10R antibodies had
even slower tumor growth, with a significance of p =
0.0005.
Blocking of IL-10 signaling, via neutralization with
antibody or due to gene knockout, led to a significant
increase in CD11b+ tumor infiltrating cells, which did not
reflect a significant increase in numbers of TAM or
CD11b+Gr1+ cells (Fig. 4B and 4C).
IL-10 does not have any effect on TC-1 proliferation
(Fig. 3). Therefore the inhibition of tumor growth should
be due to the lack of the suppressive effect that IL-10 may
have on anti-tumor immune responses.
IL-10 decreases anti-tumor antigen T cell responses
IL-10 has the potential to suppress CD8 T cell responses
and induce regulatory phenotype in T cells [36-38]. We
next asked whether the decrease in tumor growth in IL-
10 deficient mice or mice treated with neutralizing anti-
IL-10/IL-10R had any effect on lymphocyte populations.
First, we observed a significant increase in CD4 and
CD8 cell numbers in tumors from IL10 deficient mice
and mice treated with anti-IL-10/IL-10R neutralizing
antibodies. In IL-10 deficient mice, there was 3.6 fold
more CD4 lymphocytes and 4.2 fold more CD8 lympho-
cytes than what was found in tumors growing in wild type
mice, and a decrease of 3.5 fold in the B cell population in
the same tumors (Fig. 5A, asterisks indicate significant
differences between wild type and IL-10 deficient mice).
In mice treated with anti-IL10/IL-10R neutralizing anti-
bodies compared to controls, we observed a 5 fold
increase in the CD8 infiltrating cells specific for the E749-
57 peptide (Fig. 5B), an epitope previously described as the
immunodominant epitope presented by TC-1 cells in the
MHC-I context. Approximately 2 fold increase in the
number of double positive CD8 Perforin+ E7+ T cells was
observed in the IL-10R neutralized mice compared to
controls (Fig. 5B), indicating that absence of IL-10 signal-
ing enhances tumor infiltration by potentially cytotoxic T
cells. These results were confirmed to some extent by
staining tumor cryo-sections with tetramers and anti-
CD8 and anti-Granzyme B antibodies. Figs. 5C and 5E
show CD8 and tetramer staining for IL10 deficient mice
and mice treated with anti-IL10/IL-10R, respectively.
And Figs. 5D and 5F, show the same tumors stained with
anti-CD8 and anti-Grazyme B. As observed previously,
whenever IL-10 activity was blocked, we observed more
CD8 E7 specific T cells infiltrating the tumors (Fig. 5C
and 5E, arrowheads), while some nonspecific T cells were
also detected (Fig. 5C and 5E, arrows). We did not
observe binding of tetramer loaded with an irrelevant
peptide to any of the tumors. Granzyme B expression,
Figure 3 Cell cycle analysis of TC-1 cells treated with IL-10. A total 
of 25000 TC-1 cells were treated for 4 days with 0, 3, 30 or 300 ng/ml IL-
10. After this period, cells were harvested, fixed, stained and analyzed 
in a FACSCalibur. A total of 50000 cells were acquired per sample (note 
that after 4 days in culture, TC-1 cells have exponentially grown, result-
ing in a total of about 1 million cells in the end of the experiment). No 
significant differences were observed between the different condi-
tions.
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another marker of cytotoxic activity, was detected in
larger number in tumors from mice with the IL-10 signal-
ing blocked (Fig. 5D and 5F, arrows).
These results indicate that lymphocytes migrate to TC-
1 tumors when IL-10 signaling is blocked. Whether the
migration is due to altered chemokine expression, more
efficiently activated antigen presenting cells or simply
activation of T cell responses, or more likely a combina-
tion of these effects, is still to be determined. As regula-
tory T cells play a role in human cervical tumors [20] and
as we had previous indication that tumor associated mac-
rophages induced regulatory phenotype on T cells [32],
we investigated if IL-10 may have a role in expansion of
regulatory T cells in our model.
Using E7 and E6 peptides as antigens, we observed that
stimulated lymphocytes from mice treated with irrele-
vant IgG or wild type mice with TC-1 tumors had a
higher proportion of Foxp3+ CD4+ and Foxp3+CD8+ cells
than mice treated with anti-IL-10R antibody (Fig. 6A and
6B). Foxp3 is a marker of regulatory lymphocytes, which
function is to inactivate effector T cells. Our results indi-
cate that, at least in part, IL-10 facilitates tumor growth
Figure 4 Tumor growth and myeloid infiltrate in mice lacking IL-10 signaling. A. TC-1 cells, 105 cells/mouse were injected into IL-10 KO (gray 
triangles), wild type C57BL/6 mice (black diamonds), C57BL/6 mice treated (intraperitoneal injections) with 10 μg/ml anti-IL-10 or 10 μg/ml anti-IL-10R 
in alternate doses, except for the first dose, which was anti-IL-10 together with anti-IL-10R in the same day as TC-1 cells were injected (gray circles) 
(some mice were treated in the same frequency with 500 μg of anti-IL-10R, clone 1b13a, included in the last group). The averages of tumor measure-
ments of 12 mice, each condition, for the group of KO and wild type mice and 6 mice, each condition, for the group of antibody treated mice are 
represented; differences in tumor growth between control group C57BL/6 and IL-10 deficient mice (‡) or mice treated with neutralizing antibodies 
(*) were highly significant, in both cases p-value < 0.01. B and C. Analysis of tumor infiltrate by flow cytometry. Tumors were collected 15 or 17 days 
post injection. Total cell suspensions were stained with antibodies against the indicated markers and analyzed in a FACSCalibur. At least 30000 events 
were acquired per sample; * indicates significant differences between groups.
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Figure 5 Lymphocyte infiltrate in tumors from IL-10 deficient mice (A, C and D) or from anti-IL10/IL-10R neutralizing antibody treated mice 
(B, E and F). A. Single cell suspensions were stained with the indicated antibodies plus anti-CD45 and anti-F4/80. Lymphocytes were analyzed in the 
CD45+F4/80- population. B. After 6 hours incubation in tissue culture flasks, non adherent cells from total tumor suspension were harvested and 
stained with the indicated antibodies, tetramer and anti-CD45. C and E. Immunofluorescence of cryo-sections from tumors harvested from IL-10 KO 
and wild type mice or neutralizing anti-IL10/IL-1R and irrelevant IgG antibodies, as indicated. Sections were stained with anti-CD8 (in FITC, green) and 
PE (red) conjugated HPV16 E749-57 tetramer - E749-57 Tet, and irrelevant tetramer - Irrelevant Tet. Cells were counterstained with DAPI (blue). Arrowheads 
indicate double positive cells in yellow, arrows indicate cells positive only for CD8. D and F. Granzyme B expression in tumor cryo-sections from IL-10 
KO and wild type mice or mice treated with anti-IL10/IL-10R neutralizing antibodies and irrelevant IgG, as indicated. Sections were stained with anti-
CD8 (green), followed by fixation, permeabilization and staining with anti-Granzyme B (red). Tissue was counterstained with DAPI. Solid arrows indi-
cate double positive cells, arrowhead indicate CD8 only positive cell. Insets show details of cells positive only for CD8 (green) or double positive CD8/
tetramer (C and E), CD8/Granzyme B (D and F) in yellow or orange due to the sobreposition of emission from FITC and PE (tetramer) or alexa 594 (Gran-
zyme B).
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by inducing T cell regulatory phenotype and therefore
inhibiting T cell anti-tumor activity.
As mentioned before, less B cells infiltrate tumors of IL-
10 deficient mice. We observed that draining lymph
nodes of mice with TC-1 tumors have a lower T/B cell
ratio than naïve mice. When IL-10 is neutralized, the T/B
cell ratio in the lymph nodes is similar to the naïve mice
observed ratios (Fig. 6C), an indication that IL-10 may
have a role in proliferation and homing of B cells in mice
bearing TC-1 tumors.
Discussion
Several factors influence tumor fate, among them the
immune responses against tumor antigens. In the case of
tumors caused by viruses, viral antigens may be recog-
nized by the host. However, viruses as well as tumor cells
display several mechanisms of immune evasion. Among
them, the expression of suppressor cytokines like IL-10
has been described in many malignancies [15,16], includ-
ing tumors and tumor precursor lesions associated to
HPV [21-23]. Our laboratory has been working on the
characterization of the leukocyte population infiltrating
the mouse tumor model TC-1. Previous work from our
laboratory show that most of the TC-1 tumor infiltrating
leukocytes are M2-like macrophages and that depletion
of this population inhibits tumor growth and enhances
antitumor responses, showing a clear role of this popula-
tion in facilitating tumor growth [32]. Moreover, these
macrophages induce IL-10 and Foxp3 expression on lym-
phocytes [32]. Accordingly, depletion of the tumor asso-
ciated macrophage population led to an increase in
tumor infiltration by HPV16 specific CD8 T cells and
expansion of this population in the spleen [32].
In this work, we first showed that the CD45+ tumor
fraction expressed different cytokines, among them IL-
10, TNFα and TGFβ. Although several cytokines are
expressed by tumor macrophages and may have a poten-
tial role in tumor growth, this work focuses on IL-10, due
to its role as a regulator of T cell activity. TC-1 tumor
cells expressed TGFβ, but not IL-10. They did not prolif-
erate in response to IL-10 either (Fig. 3), indicating that in
our model, IL-10 does not act as a mitogen to tumor cells.
However, a correlation between IL-10 increased expres-
sion and HPV associated lesions progression to high
grade lesions have been well described in the literature
[9-11,21-23]. Moreover, women with cervical cancer have
circulating regulatory T cells that inhibit effector
response and secrete IL-10 upon antigen stimulation [20].
The molecular mechanisms underlying this correlation
have not been characterized until now. Due to the
described roles of IL-10 in the literature, like suppression
of CD8 function [37-40] and increase in B cell prolifera-
tion [41,42], as well as evidence from our laboratory
showing the role of tumor associated macrophages in
Figure 6 Induction of regulatory phenotype on T cells depends 
on IL-10. A and B. Lymph node cultures were stimulated with HPV16 
E6 and E7 peptides, 15 μg each, for 6 days. Cells were harvested and 
stained for CD4 (A), CD8 (B) and Foxp3 and analyzed by flow cytometry. 
For each sample, 105 lymphocytes were acquired. Lymph nodes were 
harvested from irrelevant IgG treated mice (IgG), anti-IL10R treated 
mice (IL10R) or TC-1 tumors bearing mice untreated (TC-1) 18 days af-
ter TC-1 cells injection. C. Flow cytometry analysis of peripheral lymph 
node suspensions stained with the indicated antibodies. Lymph node 
single cell suspensions were stained with antibodies against the indi-
cated markers and analyzed by flow cytometry. At least 30000 events 
were acquired per condition. The results are the average of 6 mice. Na-
ïve are cells obtained from mice never exposed to TC-1 tumors; TC-1 
corresponds to cells obtained from untreated mice injected with TC-1 
cells; IgG and IL-10 correspond to cells obtained from mice with tu-
mors treated with irrelevant IgG and anti-IL-10 and anti-IL-10R, respec-
tively. Asterisks indicate p < 0.05 in t-test.
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tumor growth, we decided to investigate if this cytokine is
part of the immune evasion mechanism displayed by E6/
E7 transformed cells.
In this study, we observed a decrease of tumor growth
in mouse models where IL-10 signaling was blocked: IL-
10 deficient mice or mice treated with anti-IL-10/anti-IL-
10R neutralizing antibodies. Prolonged survival and a
decrease in tumor development were observed in other in
vivo models using IL-10 deficient animals [43]. Moreover,
transgenic mice expressing IL-10 show accelerated tumor
growth that can be diminished by IL-10 neutralizing anti-
body [44,45]. We realize that the TC-1 cell line is trans-
formed with high risk HPV16 oncogenes E6/E7 and EJ-
ras [34]. Ras-associated tumors may induce IL-10 expres-
sion as a form of evasion. Indeed, this seems to be the
case of some colon cancers [17]. On the other hand, thy-
roid tumors, which frequently display mutation in ras,
respond to an autocrine IL-10 signalization loop where
tumor cells secrete and proliferate in response to IL-10
[19]. In colon cancer, although there is discussion in the
literature, IL-10 may be used as therapy once it could
counter-act the action of pro-inflammatory cytokines
that cause chronic inflammation leading to cancer [46].
In our model, TC-1 cells do not secrete or proliferate in
response to IL-10. Therefore the role IL-10 plays on TC-1
tumor growth is probably associated only to the regula-
tion of immune responses and its source, as demon-
strated in this work, is the myeloid tumor infiltrate.
In parallel to a reduction in tumor growth, we observed
in IL-10 deficient mice or mice treated with anti-IL-10/
anti-IL-10R neutralizing antibodies that there was an
increase tumor infiltration by CD4 and CD8 lympho-
cytes, which were rare in tumors from control wild type
mice. Importantly, there was a significant increase in CD8
E7 specific cells with a cytotoxic phenotype in mice that
had the IL-10 signaling blocked compared to controls.
When stimulated with E6 and E7 peptides, lymphocytes
from control mice and mice treated with irrelevant IgG
had a significantly higher proportion of Foxp3 regulatory
cells than lymphocytes from mice with neutralized IL-10
signaling. This result indicates that IL-10 suppresses T
cell activity by inducing a regulatory phenotype on CD4
and CD8 lymphocytes. We cannot, however, rule out a
possible effect of tumor microenvironment that would
facilitate T cell recruitment. Probably, a combination of
both events occurs in our model. There was, for example,
a significant increase in the CD11b+ myeloid population
in IL-10 deficient mice and mice treated with anti-IL-10/
IL-10R neutralizing antibodies when compared to con-
trols, indicating a difference in the tumor microenviron-
ment due to IL-10 depletion. In HPV16 tumor models, a
role for CCL2 in the recruitment of macrophages for the
tumor site was described by Pahler and collaborators
[47]. In our laboratory, using a keratinocyte cell line
expressing HPV16 E6/E7 and its parental cell line, we
were able to show that the CCL2 effect on myeloid cell
recruitment is dependent on E6/E7 expression [Bolpetti
in preparation]. Interestingly, IL-10 inhibits CCL2
expression 48, in a way that it is possible that the increase
in CD11b+ cells that infiltrate tumors from either IL-10
deficient mice or mice treated with neutralizing anti-
IL10R antibody may be due to an increase in CCL2
expression.
Another effect of IL-10 neutralization in mice was the
decrease in tumor cell infiltration by B cells and reduc-
tion of the B cell numbers in peripheral lymph nodes.
This result is not surprising since one described role for
IL-10 is B cell proliferation [41,42]. It is possible that IL-
10 causes a skewing in adaptive response toward humoral
response, which may contribute to the inhibition of T cell
function or simply which is ineffective against tumor
cells.
Conclusions
IL-10 production by tumor associated myeloid cells,
mainly macrophages, induces expansion of HPV specific
regulatory T cells, possibly inhibiting effector T cell anti-
tumor activity. We believe our work suggests that this is
one of the possible mechanisms behind the epidemio-
logic data correlating HPV associated tumor progression
and increase in IL-10 expression.
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